Page 95 - The Flying Publisher Guide to Hepatitis C Treatment

References | 95

Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance
mutations to hepatitis C virus protease and polymerase inhibitors in
treatment-naïve patients. Hepatology 2008;48:1769-78.
Kuo A, Tan V, Lan B, et al. Long-term histologic effects of preemptive antiviral
therapy in liver transplant recipients with hepatitis C virus infection. Liver
Transpl 2008;14:1491-7.
Kwo PY, Lawitz EJ, McCone, et al. Efficacy of boceprevir, an NS3 protease
inhibitor, in combination with peginterferon alfa-2b and ribavirin in
treatment-naive patients with genotype 1 hepatitis C virus infection
(SPRINT-1): an open-label, randomized, multicentre phase 2 trial. Lancet.
2010;376:705-16.
Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C
by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
PLoS One 2011;6:e17232.
Lake J, Patel D, David K, et al. The association between MMF and risk of
progressive renal dysfunction and death in adult liver transplant recipients
with HCV. Clin Transplant 2009;23:108-15.
Langrehr JM, Puhl G, Bahra M, et al. Influence of donor/recipient HLA-matching
on outcome and recurrence of hepatitis C after liver transplantation. Liver
Transpl 2006;12:644-51.
Lee SR, Kardos KW, Schiff E, et al. Evaluation of a new, rapid test for detecting
HCV infection; suitable for use with blood or oral fluid. J Virol Methods
2011;172:27-31.
Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C
who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig
Dis Sci 2008;53:1961-6.
Lindhal K, Stahle L, Bruchfeld A, Schwarcz R. High-dose ribavirin in combination
with standard dose peginterferon for treatment of patients with chronic
hepatitis C. Hepatology 2005;41:275-9.
Mallet V, Gilgenkrantz H, Serpaggi J, et al. The relationship of regression of
cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-
403.
Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12
weeks) course of antiviral therapy and re-treatment efficacy of a prolonged
course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Hepatology 2009;49:358-63.
Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12
vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial treatment of
chronic hepatitis: a randomised trial. Lancet 2001;358:958-65.
Marcellin P, Freilich B, Andreone P, et al. HCV-RNA status at week 12 of
treatment with PEG-Interferon alfa-2a/RBV predicts SVR in patients with
prior non-response to pegylated interferon alfa-2b/RBV: results from the
REPEAT study. J Hepatol 2008;48:S301.
Marcellin P, Gish RG, Gitlin N, et al. Safety and efficacy of viramidine versus
ribavirin in ViSER2: randomized, double-blind study in therapy-naive
hepatitis C patients. J Hepatol 2010;52:32-8.